Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachnoid Hemorrhage

Model scores of the 29,894 trials active now.

Model score 18% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (107 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-01-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Drug's FAERS reports with a death: 69.2% (raises risk) · Drug's FDA history
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: randomizationintravenoushoursplaceboinfusion
  Phrases that lowered it: trialefficacyclinicalmedicationgroup
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Responsible party: principal investigator (lowers risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Maximum age: 70 (lowers risk) · Who can join
• Sponsor's past trials: 2 (lowers risk) · Sponsor's track record
• Phase: 2/3 (lowers risk) · Design
• Number of arms: 2 (raises risk) · Design
• Keywords listed: 0 (lowers risk) · Design
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Clazosentan in Aneurysmal Subarachnoid Hemorrhage NCT00940095 · started 2009 · scored riskier than 97% of active trials terminated
• Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain NCT03585270 · started 2019 · scored riskier than 96% of active trials completed
• Levosimendan as Treatment of Aneurysmal SubArachnoid Haemorrhage NCT05664191 · started 2023 · scored riskier than 95% of active trials completed
• Evaluation of CN-105 in Subject With Acute Supratentorial Intracerebral Hemorrhage NCT03711903 · started 2019 · scored riskier than 56% of active trials completed
• Subarachnoid Hemorrhage Recovery And Galantamine NCT02872857 · started 2016 · scored riskier than 87% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.